SNDL Passes EU-GMP Audit, Opening Door to International Medical Cannabis Markets
SNDL is trading near its 52-week low of $1.165 (5.6% above the low).
Summary
SNDL's Atholville facility successfully completed an EU-GMP audit, a critical regulatory step for exporting medical cannabis to Europe and other international markets. The company expects formal certification within 90 days. Atholville is a major asset with 110,000 sq ft of canopy and current production of 4,500 kg per quarter, scalable to over 30 tonnes with investment. This milestone follows the recent Parallel acquisition and Q2 loss, adding a new growth vector. International medical cannabis sales could materially improve margins and diversify revenue beyond Canada's competitive retail market.
At the time of this announcement, SNDL was trading at $1.23 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $300.4M. The 52-week trading range was $1.17 to $2.89. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.